![PERFORMANCE EVALUATION THROUGH FINANCIAL RATIOS: COMPARATIVE ANALYSIS OF PFIZER, INC. AND NOVARTIS AG | Semantic Scholar PERFORMANCE EVALUATION THROUGH FINANCIAL RATIOS: COMPARATIVE ANALYSIS OF PFIZER, INC. AND NOVARTIS AG | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d56983289792709fecb24ed0a1ed74b38c0144fb/28-Table12-1.png)
PERFORMANCE EVALUATION THROUGH FINANCIAL RATIOS: COMPARATIVE ANALYSIS OF PFIZER, INC. AND NOVARTIS AG | Semantic Scholar
![IFRIC 17 para 15, IFRS 5, gain on distribution of non-cash assets disclosed on face of income statement, discontinued operations disclosure – Accounts examples IFRIC 17 para 15, IFRS 5, gain on distribution of non-cash assets disclosed on face of income statement, discontinued operations disclosure – Accounts examples](https://httpifrsexamples.files.wordpress.com/2024/02/novartis1.png?w=808)
IFRIC 17 para 15, IFRS 5, gain on distribution of non-cash assets disclosed on face of income statement, discontinued operations disclosure – Accounts examples
![Novartis acquires gene therapy candidate from Avrobio in unusual deal | HealthCare Middle East & Africa Magazine Novartis acquires gene therapy candidate from Avrobio in unusual deal | HealthCare Middle East & Africa Magazine](https://www.healthcaremea.com/wp-content/uploads/2022/03/Novartis-11.jpg)
Novartis acquires gene therapy candidate from Avrobio in unusual deal | HealthCare Middle East & Africa Magazine
![Novartis' $13B influx may go to bolt-on deals as late-stage drugs reach market | S&P Global Market Intelligence Novartis' $13B influx may go to bolt-on deals as late-stage drugs reach market | S&P Global Market Intelligence](https://www.snl.com/articles/392810274.png)